

1 **The metabolic, virulence and antimicrobial resistance profiles of colonizing**
2 ***Streptococcus pneumoniae* shift after pneumococcal vaccine introduction in urban**
3 **Malawi**

4 Andrea Gori* ^{1,†}, Uri Obolski* ^{2,3}, Todd D. Swarthout* ^{1,4}, José Lourenço ⁵, Caroline M. Weight ¹,
5 Jen Cornick ⁴, Arox Kamng'ona ^{4,6}, Thandie S. Mwalukomo ^{4,6}, Jacqueline Msefula ⁴, Comfort
6 Brown⁴, Martin C. Maiden ⁵, Neil French ⁷, Sunetra Gupta ⁵, Robert S. Heyderman ¹

7 1 University College London, NIHR Global Health Research Unit on Mucosal Pathogens, Division
8 of Infection & Immunity, London, United Kingdom,

9 2 Tel-Aviv University, Faculty of Medicine, School of Public Health, Tel Aviv, Israel

10 3 Tel-Aviv University, Faculty of Exact Sciences, Porter School of the Environment and Earth
11 Sciences, Tel Aviv, Israel

12 4 Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi

13 5 University of Oxford, Department of Zoology, Oxford, United Kingdom

14 6 Kamuzu University of Health Sciences, Blantyre, Malawi

15 7 University of Liverpool, Clinical Infection, Microbiology and Immunology, Institute of Infection
16 Veterinary & Ecological Science, Liverpool, United Kingdom

17

18 *contributed equally

19 †To whom correspondence should be addressed: a.gori@ucl.ac.uk

20 **Abstract**

21 *Streptococcus pneumoniae* accounts for at least 300,000 deaths from pneumonia, septicaemia and
22 meningitis among children under 5-years-old worldwide. Protein–polysaccharide conjugate vaccines
23 (PCVs) are highly effective at reducing vaccine serotype disease but emergence of non-vaccine
24 serotypes and persistent nasopharyngeal carriage threaten to undermine this success. Here, we address
25 the hypothesis that following vaccine introduction in high disease and carriage burden settings, adapted
26 pneumococcal genotypes emerge with the potential to facilitate vaccine escape. We show that beyond
27 serotype replacement, there are marked changes in *S. pneumoniae* carriage population genetics
28 amongst 2804 isolates sampled 4-8 years after the 2011 introduction of PCV-13 in urban Malawi.
29 These changes are characterised by metabolic genotypes with distinct virulence and antimicrobial
30 resistance (AMR) profiles. This included exclusive genes responsible for metabolism and carbohydrate
31 transport, and toxin-antitoxin systems located in an integrative-conjugative region suggestive of
32 horizontal gene transfer. These emergent genotypes were found to have differential growth, haemolytic,
33 or epithelial adhesion/invasion traits that may confer advantage in the nasopharyngeal niche. Together
34 these data show that in the context of PCV13 introduction in a high burden population, there has been
35 a shift in the pneumococcal population dynamics with the emergence of genotypes that have undergone
36 multiple adaptations extending beyond simple serotype replacement, a process that could further
37 undermine vaccine control and promote the spread of AMR.

38

39 **Introduction**

40 *Streptococcus pneumoniae* (the pneumococcus), a common commensal of the upper respiratory tract,
41 is responsible for a high burden of severe pneumonia, septicaemia and meningitis [O'Brien, *et al.*,
42 2013], mainly affecting children under 5-years-old, the immunocompromised and the elderly.
43 Pneumococcal disease causes almost 300,000 deaths annually in under-5's worldwide, and
44 disproportionately affects people in resource-poor settings, where 57% of the total pneumococcal deaths
45 occur [Wahl *et al.*, 2015]. This high burden of pneumococcal disease is largely vaccine preventable
46 [O' Brien, *et al.* 2009; O' Brien 2013; Ngocho, *et al.*, 2019]. Indeed, reports from The Gambia, South
47 Africa, Kenya and Malawi [Roca, *et al.*, 2015; Nzenze, S. A. *et al.* 2015; Cohen *et al.*, 2017; Hammitt
48 *et al.*, 2019, Bar-Zeev, *et al.*, 2021] show that pneumococcal conjugate vaccines (PCV), targeting the
49 polysaccharide capsule of the most common disease-causing pneumococcal serotypes (currently
50 PCV10 or PCV13), have been highly effective in reducing invasive pneumococcal disease (IPD).
51 However, the highly adaptable nature of *S. pneumoniae* has the potential to undermine this success.
52 Through the expression of approximately 100 capsule serotypes, the pneumococcus has the ability to
53 adapt to change, by mutation and by the capacity to readily acquire new traits through horizontal gene
54 transfer from other pneumococci and related streptococci occupying the same niche [Salvadori *et al.*,
55 2019].

56 In the context of PCV introduction, vaccine type (VT) replacement IPD is widespread in resource-rich
57 settings [Southern, *et al.*, 2018; Vestrheim, *et al.*, 2010] and is being increasingly reported on the
58 African continent [Kwambana-Adams, *et al.*, 2017, Vadlamudi, *et al.*, 2019]. In addition, we and
59 others have shown that despite excellent vaccine uptake in many African countries, there is
60 considerable residual VT nasopharyngeal carriage in both PCV-vaccinated and PCV-unvaccinated
61 populations several years after PCV introduction [Swarthout, *et al.*, 2020, Roca, *et al.*, 2015; Nzenze,
62 S. A. *et al.* 2015; Cohen, *et al.*, 2017]. Routine PCV programmes have also been shown to reduce the
63 burden of antimicrobial resistant (AMR) *S. pneumoniae* VT disease and carriage in some settings [Ben-
64 Shimol, *et al.*, 2018; Tin Htar, *et al.*, 2019]. However, the impact has not been uniform, with the
65 emergence of certain AMR serotypes, most notably 7F and 19A [Lee, *et al.*, 2017; Ghahfarokhi, *et al.*,
66 2020; Lo, *et al.*, 2019]. Furthermore, our modelling suggests that under vaccine pressure, antimicrobial
67 resistant non-VT (NVT) strains could replace susceptible NVT strains through the removal of

68 competition from vaccine-susceptible VTs [Obolski *et al.*, 2018].

69 Emerging evidence from Africa, Europe and the US suggests that PCV introduction has driven
70 genomic alterations in *S. pneumoniae* populations, contributing to capsular switching, selection of
71 specific lineages and genetic recombination [Chaguza, *et al.*, 2018; Azarian *et al.*, 2018; Croucher, *et*
72 *al.*, 2014; Croucher, *et al.*, 2015; Sheppard, *et al.*, 2019]. We have previously described a theoretical
73 framework whereby pneumococcal vaccines targeting particular serotypes drive the emergence of
74 NVT *S. pneumoniae* strains with metabolic and virulence-associated characteristics similar to the VTs
75 commonly circulating prior to vaccine introduction [Watkins, *et al.*, 2015].

76 Here, to explore the genotypic and phenotypic basis for this framework, we have used a large, well-
77 characterised pneumococcal carriage strain collection from an urban population in Blantyre, Malawi
78 (2015-2018), established starting 4 years after the introduction PCV13 into the national immunisation
79 programme. PCV13 was introduced 12 November 2011 using a 3+0 schedule, with primary doses
80 given at 6, 10 and 14 weeks of age. Field studies in Malawi have reported high PCV13 uptake of 90%–
81 95% [Mvula, *et al.*, 2016], similar to the 92% PCV13 coverage recently reported by WHO/UNICEF.
82 [WHO and UNICEF estimates of immunization coverage, 2018.
83 https://www.who.int/immunization/monitoring_surveillance/routine/coverage/WUENIC_notes.pdf]

84 We hypothesised that in this population with a high force of infection [Lourenço, *et al.* 2019] and a
85 high frequency of multiple serotype carriage [Swarthout, *et al.*, 2020], there would be an increase in
86 pneumococcal diversity, adaptability and potentially AMR. We have therefore developed a metabolic
87 core genome allelic profiling method, which has allowed us to analyse 2804 *S. pneumoniae* carriage
88 isolates collected over 4 years of surveillance. We show that discreet “metabolic genotypes” have
89 expanded amongst both VT and NVT serotypes up to 7 years after vaccine introduction. These
90 expanding metabolic genotypes are characterised by accessory genes linked to virulence and AMR, as
91 well as *in-vitro* phenotypes that suggest adaptation. Together these data highlight mechanisms of
92 vaccine escape beyond serotype replacement that, if not addressed, may undermine current and future
93 vaccine strategies.

94 **Results**

95 **Homogeneity of the Blantyre pneumococcal carriage strain collection across age-cohorts using**
96 **classical serotyping and genotyping methods.** In our population-based carriage surveillance in
97 Blantyre, Malawi (8 surveys between 2015-2019), we have shown high persistent residual VT carriage
98 among PCV-vaccinated children 3–5-year-old (16.7%) and PCV-unvaccinated children 6–8-year-old
99 (15.7%) and HIV-infected adults 18-40 years old on antiretroviral therapy (ART; 8.9%) [Swarthout,
100 *et al.*, 2020]. Using this Blantyre pneumococcal carriage strain collection, WGS libraries were
101 developed using a random subset of isolates from each of the eight surveys (Table 1).

102 Among the final dataset of 2804 sequenced carriage isolates, we observed a decline of vaccine-type
103 serotype 1 and 6B carriage isolates, and an increase in frequency amongst several NVTs over time,
104 in particular 23B and 38 (Figure 1). However, the majority of VTs and NVTs persisted over-time and
105 were equally distributed across age cohorts (Figure 1, Figure S1). Two hundred sequence-types (ST)
106 were identified on the basis of the allelic profiles of a standard set of seven housekeeping genes (see
107 Methods). Most STs were present in each cohort (Figure S1a), with the exception of the STs
108 circulating at very low frequencies, including ST347, ST4084, ST10880 and ST10992, which were
109 not identified among the isolates from the HIV-infected adults. Similarly, identified serotypes and
110 global pneumococcal sequencing clusters (GPSCs) were evenly distributed across the age-cohorts
111 surveyed (figure S1b and S1c). Given this spread of serotyping and genotyping characteristics
112 throughout the collection, all isolates were aggregated into a single dataset for the subsequent
113 analyses.

114

115 **Serotype switching amongst both vaccine and non-vaccine serotypes.** On the basis of the
116 sequence-typing, we identified 44 separate serotype switching events in the Blantyre collection,
117 described by a total of 22 STs which corresponded to more than one serotype (Table 2).
118 Directionality of these switch events was determined by considering the genetic relatedness of the
119 strains and assuming that the most common serotype (capsule type in a dominant lineage) within an
120 ST was the serotype from which the switch originated [Chaguza, *et al.*, 2017]. Rather than a clear
121 shift from VTs towards NVTs, low-frequency VT or NVT variants were identified to undergo

122 switching throughout the carriage surveys in several ST and GPSC lineages (Figure S2a and S2b).
123 These data support the emerging evidence that even in the context of vaccine introduction, the
124 process of serotype switching is not limited to VTs (e.g. ST7653 6C/6D or ST3214 35A/11A). We
125 suggest that although a serotype switch may be directly vaccine-induced, switched serotypes may
126 have occurred stochastically and then emerged alongside other vaccine-associated changes in
127 population structure. Indeed, it seems likely that selection forces that are more complex than
128 serotype-directed vaccine pressure alone facilitate many of such switches such as environmental and
129 antimicrobial pressures [Croucher, *et al.*, 2015].

130

131 **Shifts in metabolic gene profiles of the pneumococcal population:** To further identify dynamic
132 changes in the pneumococcal population structure beyond serotype switching, we defined metabolic
133 genotypes (*metabolic types, MTs*) based on our previously described theoretical framework
134 [Watkins, *et al.*, 2015]. Each MT was classified on the basis of differences in core genes involved in
135 metabolism and energy production, following functional annotation of the pan-genome of the
136 pneumococcal population. This typing method therefore relies on sequence differences between
137 genes involved in bacterial metabolism (i.e. function), rather than lineages defined exclusively by
138 bacterial evolutionary history.

139 We grouped the Blantyre pneumococcal carriage isolates into 148 discrete MTs (Figure 2). As
140 shown in the clustering tree, these MTs were neither independent of serotype nor did they completely
141 overlap with serotype. For instance, the 14 different serotype 19F MTs were spread across the
142 clustering tree. Overall, the majority of MTs did not significantly change in frequency when
143 comparing early and later surveillance isolates ($p > 0.05$; Fisher's exact test), highlighting a high
144 residual diversity within the bacterial population (figure S3a and S3b). Nonetheless, our analysis
145 highlighted a shift in the pattern of several MTs: for instance, with the NVTs 10A, 17F, 34, 38 and
146 23B which showed a significant increase in MTs 74, 109, 33, 120 and 93 (Figure S3a and S3b,
147 $p < 0.05$, Fisher's exact test).

148 In total we observed 32 instances in which VTs switch capsular serotype to NVT, or vice versa,
149 while maintaining the same metabolic profile which is in line with a vaccine-induced metabolic shift

150 as described in our previous models [Watkins, *et al.*, 2015]. However, we cannot infer vaccine
151 causality from this dataset.

152

153 **Metabolic genotypes increasing in frequency are characterised by increased AMR:** To address
154 the hypothesis that vaccination drives changes in the pattern of AMR by removing the competition of
155 non-AMR VTs [Obolski, *et al.*, 2018], we assessed whether the emerging MTs amongst the NVTs
156 10A, 17F, 23B, 34 and 38 were also associated with increased AMR. We determined resistance
157 genetically to penicillin, an important first-line antibiotic for pneumococcal disease, together with
158 chloramphenicol, erythromycin and tetracycline, which are also commonly used antibiotics in this
159 population. Higher penicillin MICs (minimum inhibitory concentration) were observed in the later
160 surveillance period compared to the early surveillance period (Wilcoxon rank sum test, $p < 0.01$)
161 (Supplementary Figure S3e). The majority of the serotypes and MTs identified in this dataset ($n=39$
162 and $n=79$ respectively) were significantly associated with either a positive or negative association with
163 penicillin AMR (i.e. MIC > 0.06 ug/ml, $p < 0.05$; Fisher's exact test), indicating that this phenotypic
164 characteristic is likely linked to the isolate's genotype [Chaguza, *et al.*, 2019] (Supplementary Figure
165 S3c and S3d).

166 We observed several instances in which emerging metabolic genotypes were associated with higher
167 AMR. Among NVTs 17F, 10A, 23B, 34 and 38 we show that MTs 109, 74, 93, 22 and 120
168 (respectively, Figure 2) were more frequently identified in the later surveillance period ($p < 0.05$;
169 Fisher's exact test) (Figure 3), indicating a shift in the dominant genotype observed within each
170 serotype. In four of these NVTs (17F, 10A, 23B and 38), the emergence of MTs in later surveillance
171 was associated with increased AMR: either in terms of an increased MIC for penicillin (genetically
172 assessed, Figure 3) or in terms of presence of other antibiotic resistance genes such as *tetM* and
173 *ermB*; Supplementary (Figure S4). In serotypes 17F, 23B and 38, there was an increase in the
174 frequencies of MT114, MT97 and MT122, respectively. In each case, the MT that emerged showed a
175 higher penicillin MIC, compared to MTs common in the bacterial population at earlier surveys
176 stages. Interestingly, the increased frequency of MT46 of serotype 34 in later surveillance surveys

177 without exhibiting an increase in AMR suggests a variety of forces that drive the selection and
178 restructuring of bacterial populations.

179 There were no significant changes ($p > 0.05$, Fisher's exact test) in carriage frequency of the majority
180 of the VTs over the duration of the surveillance period - i.e. they did not increase nor decrease when
181 comparing the early and later periods of surveillance. These included, 3, 19F and 23F (Figures 1 and
182 S3). Serotypes 3 and 23F in particular were found at relatively high frequencies after vaccine
183 introduction in other settings [Kandasamy, *et al.*, 2019; Lewnard and Hanage, 2019]. Contrary to
184 what was described with NVTs, the persistent VTs in this dataset were characterised by the presence
185 of a dominant MT (MT 9 for serotype 3, MT 3 for serotype 23F) consistently present during the
186 survey period, showing increased penicillin MIC and the presence of antimicrobial resistance genes
187 (Figure S5).

188 Within those serotypes where we identified genotype switch events (namely, 17F, 10A, 23B, 38 and
189 23B), we investigated genetic relatedness amongst MTs and time-calibrated phylogeny, in order to
190 reconstruct the emergence of those recent dominant MTs. We assessed the genetic relatedness between
191 MTs, hence their likelihood to have recently expanded clonally, by calculating the core genome SNP
192 (single nucleotide polymorphism) divergence between MTs (Figure S6). For serotypes 38, 17F and 34,
193 recently identified MTs were characterized by lower genotypic difference (lower SNP variance,
194 $p < 0.05$, F-test for variances, Figure S6), indicating that these isolates expanded clonally. This recent
195 clonal expansion was confirmed by the temporal signal identified in the phylogeny (Figure S7). Root-
196 to-tip regression highlighted that the emergence of the recently identified lineages (MT109 and MT120)
197 in serotype 17F and 38 was likely to have happened before the year 2011 (17F MT114: 2000.9 [95%
198 CI 1988.35 - 2008.1] node 95, 2009.7 [2005.7 - 2012.3] node 94; for 38 MT122: 2009.3 [2000.3 -
199 2013.3] node 85, 2007.5 [1996.7 - 2012.2] node 84, 2004.1 [1985.2 - 2011.4] node 83). Thus, none
200 of these MTs are likely to have originated after PCV13 introduction, but rather we propose that they
201 existed as variants at low frequency before vaccine introduction that underwent clonal expansion. It
202 was not possible to temporally calibrate the phylogeny of serotypes 23B, 10A and 34, hence we could
203 not infer the time of emergence of those lineages. This may be due to the smaller sample size of some
204 lineages (i.e. in serotype 10A) or to lineages that originated much earlier than their isolation in this

205 study.

206

207 **Emerging metabolic genotypes show multiple adaptations:** Having demonstrated a shift in MTs in
208 serotypes 10A, 17F, 23B, 34 and 38 associated with increased AMR during the post-vaccine
209 introduction observation period, we then assessed whether these emerging MTs had associated
210 virulence characteristics that could convey a competitive advantage. To do this, we investigated the
211 accessory genome using a pan-genome wide association study approach (pan-GWAS, Gori, *et al.*,
212 2020). We identified 93, 73, 51, 30 and 175 genes present exclusively in the most common emerging
213 metabolic profiles of serotypes 10A, 17F, 23B, 34 and 38, respectively (Figure S8; full gene list is
214 reported in Supplementary Table S1; examples of genes associated to each MT analysed are shown in
215 Table 2). Functional annotation showed that these included genes responsible for metabolism and
216 carbohydrate transport. In serotype 38 MT120, for instance, mannose- and sorbose-specific transporter
217 genes, absent in other MTs, were identified. MT93 serotype 23B was characterised by lactose and
218 galactiol transporters (Table 2) which were absent in other MTs. The emerging MTs were also
219 characterised by the presence of bacterial defense systems, such as multidrug resistance ABC
220 transporters, restriction enzymes and antimicrobial resistance genes (Table 2).

221 The MT93 and MT120 of serotypes 23B and 38 accessory genomes encode several Toxin-Antitoxin
222 (TA) systems. Variants of the *pezAT* system was present in MT93 and MT120 and a *yefM-yoeB* system
223 was present in MT120. This particular TA-system is located in a previously described integrative-
224 conjugative region (ICE) [Brown *et al.*, 2003], which is absent from the non-MT120 strains. The ICE
225 region is present in several non-pneumococcal *Streptococci*, such as *dysgalactiae* and *suis* [Huang, *et al.*,
226 2016], suggesting that its acquisition may have occurred via horizontal gene transfer (HGT). This
227 ICE also carries specific metal transporters, phage resistance and competence systems, as well as a
228 previously described agglutinin receptor involved in colonisation [Brown, *et al.*, 2003].

229 Together, these data demonstrate that the emerging MTs have acquired a range of potential adaptations
230 (Figure 4). In populations with a high force of infection and host vulnerabilities such as malnutrition
231 and HIV, this potential for competitive advantage in nutrient transport, cellular metabolism,
232 nasopharyngeal epithelial colonisation and AMR could lead to a resurgence in invasive NVT

233 pneumococcal disease.

234

235 **Phenotypic characterisation of emerging MT reveals adaptations that may confer competitive**
236 **advantage:** To further explore this potential competitive advantage amongst emerging NVT metabolic
237 genotypes with increased AMR, we compared MT shifts within serotype 38 and serotype 23B in
238 several *in vitro* phenotypic assays. These aimed at representing some of the challenges of bacterial
239 lifestyle in the nasopharyngeal niche. Firstly, we cultured combinations of different MTs in standard
240 growth medium [Ram, *et al.*, 2019]. The growth parameters and the *in-vitro* fitness were calculated by
241 *Curveball* for MTs 28 and 120 for serotype 38 and MTs 23 and 93 for serotype 23B (Figure 5). This
242 software fits the growth curves of the different bacterial strains to several growth models and attempts
243 to predict which one would have a competitive advantage over the other while sharing resources.

244 Within serotype 23B MT93, the emergent strain reached a higher maximum optical density (OD) than
245 MT23 (Figure 5). Using the Baranyi-Roberts model [Ram, *et al.*, 2019] to approximate co-culture
246 growth, we found that MT93 is expected to have a higher *in-vitro* fitness than MT24. Within serotype
247 38 MT120, the emergent strain, grew at a lower rate and to a lower maximum OD than MT28 (Figure
248 5) and therefore had a lower predicted fitness than MT28. Thus, while some emergent MTs have a
249 growth advantage, others do not.

250

251 The epithelial colonisation process is a prerequisite for both disease and onward transmission to
252 another host [Weiser *et al.*, 2018]. We therefore then tested these MT pairs in a well-standardised
253 Detroit 562 human nasopharyngeal epithelial infection model [Weight, *et al.*, 2019]. Within serotype
254 38, we observed no difference in the ability to colonise the epithelial cells between MTs 28 and 120.
255 In contrast, serotype 23B, MT93 was internalised into epithelial cells at a higher frequency than MT23
256 (Figure 6a and 6b) even though both genotypes were characterised by the same ability to associate
257 with epithelial cells. We have previously suggested that differences in this so-called epithelial
258 “microinvasion” may be fundamental to the outcome of colonisation, explaining strain differences in
259 the potential of *S. pneumoniae* to cause invasive disease, persist during carriage and be transmitted
260 from person-to-person [Weight, *et al.*, 2019].

261 Other phenotypic characteristics in different MTs were assessed, such as their ability to stimulate the
262 production of the phagocyte chemoattractant IL-8 in epithelial cells (Figure 6c) and their haemolytic
263 potential, a measure of functional pneumolysin production (Figure 6e). Serotype 38's MT120
264 stimulated lower IL-8 production, compared to MT28, while the two MTs in serotype 23B did not
265 stimulate a higher IL-8 production when compared to the non-infected control. The haemolytic
266 potential of serotype 23B's MT 23 was higher than serotype 23B's MT93 (Figure 6e), while there was
267 no significant difference was identified between serotype 38 strains.

268 Together these data suggest that the emerging MTs have not arrived at a single adaptive profile but
269 have undergone a variety of changes (growth; epithelial invasion; inflammation; and pneumolysin
270 production) that may have enabled them to become more prominent in the context of vaccine
271 introduction.

272 **Discussion**

273 How a pneumococcal population evolves both under natural or vaccine-induced pressures remains an
274 open question. It has been long known that *S. pneumoniae* is characterised by a high level of genome
275 plasticity, and this species diverges more quickly than many other mucosal bacterial species
276 associated with vaccine preventable disease [Tettelin and Hollingshead, 2004; Croucher *et al.*, 2011].
277 Here, using a large post-PCV introduction pneumococcal carriage surveillance dataset from an urban
278 population in Malawi, we describe the emergence of pneumococcal lineages with unique virulence,
279 AMR and metabolic characteristics. Rather than using the populational structural methods of the
280 Pneumococcal Molecular Epidemiology Network (PMEN) [McGee, *et al.*, 2001] or the Global
281 Pneumococcal Sequencing (GPS) consortium [Gladstone, *et al* 2019], our genotyping approach
282 defined pneumococcal lineages based on metabolic genotypes (MT) [Watkins, *et al.*, 2015].

283 We show that in addition to serotype replacement, there has been a shift in the profile of AMR MTs
284 among NVTs characterised by exclusive genes responsible for metabolism and carbohydrate
285 transport, and toxin-antitoxin systems located in an integrative-conjugative region suggestive of
286 horizontal gene transfer. Phenotypically, these emergent genotypes were found to have differential
287 growth, haemolytic, inflammatory or epithelial adhesion/invasion traits that may confer advantage in

288 the nasopharyngeal niche. These findings support theoretical models that predict that PCV
289 introduction disrupts complex competitive interactions between colonising pneumococci, with the
290 potential to promote replacement with fitter, more virulent, and more antimicrobial resistant existing
291 pneumococcal lineages [Watkins, *et al.*, 2015; Obolski, *et al.* 2018]. We postulate that if these
292 emergent NVT MTs become fixed in the population, they may lead to a lower vaccine effectiveness
293 and vaccine escape. We also observed stable MTs among VTs and although our observations are
294 limited to the post-PCV13 era, we speculate that these genotypes may confer a competitive
295 advantage leading to inadequate PCV13 effectiveness in the control of VT carriage, including
296 serotypes 3, 19F and 23F.

297

298 The overall effect of the shift in MTs that we have observed is dependent on their transmissibility and
299 their relative invasiveness [Lo, *et al.*, 2019]. These MTs have emerged within serotypes that are known
300 to be important contributors to IPD and are commonly carried. Serotype 38 has high heterogeneity in
301 its invasive potential in South Africa and the USA [Lo, *et al.*, 2019]; serotype 23F ST2059/MT3 was
302 reported to have a higher risk for invasiveness in strains isolated in South Africa and in the USA;
303 serotype 23B ST4423/MT97 was identified in IPD in South Africa and Israel; and serotype 35B, which
304 also expanded in frequency in this study, was highlighted as an expansion serotype in Malawi IPD [Lo,
305 *et al.*, 2019; Gladstone, *et al.*, 2019]. Moreover, serotypes 23B and 38 are among the top 10% of
306 serotypes causing IPD after vaccine introduction in Europe, Asia and US [Balsells, *et al.*, 2017].

307

308 The emergence and expansion of particular NVTs in the period after PCV introduction has been widely
309 reported [Lo, *et al.*, 2019], and the serotype switching processes and dynamics highlighted here have
310 also been reported by others [Chaguza, *et al.*, 2019; Gladstone, *et al.*, 2019]. For instance, the serotype
311 switch event involving ST8672 (serotypes 3 and 7F) was also identified in a post-vaccination carriage
312 study in northern Malawi [Chaguza, *et al.*, 2019]. Similarly, the Global Pneumococcal Sequencing
313 study, identified ST10599 and ST989 as part of switch events, highlighting how these mechanisms are
314 common in pneumococcal genotype and serotype dynamics [Lo, *et al.*, 2019].

315

316 To assess the generalisability of our findings, we undertook a wider comparison using pneumococcal
317 genomes sequences from other African countries [Lo, *et al.*, 2019; Gladstone, *et al.*, 2019]. This
318 revealed the presence of analogous MTs outside Malawi, leading to the hypothesis that these MTs
319 have become more prevalent across the continent following PCV introduction. In particular, MT97
320 and MT122 (associated with serotypes 23B and 38 respectively) have been identified after vaccine
321 introduction in invasive pneumococcal disease isolates in both South Africa and The Gambia
322 [Gladstone, *et al.*, 2019]. However, interestingly, we found that rather than originating from a common
323 source, differences in the core genome SNPs among MT122 strains isolated in South Africa and in
324 Malawi (~6000 SNPs, Figure S8) suggest that these different lineages originate from different
325 ancestors that have subsequently converged to the same MT.

326 A theme that has emerged from our analysis is that although the emergent MTs have successful
327 metabolic, virulence and AMR properties that may confer a competitive advantage over other MTs,
328 we did not identify genetic or phenotypic traits that suggest a single adaptive profile amongst the
329 emergent MTs. In contrast, we identified multiple different adaptations that may provide an
330 advantage in distinct ecological niches. With regards to the accessory genome, for instance, some
331 MTs are characterised by particular sugar transporters, TA-systems and bacteriocins production
332 systems, which would confer competitive advantage while sharing resources. In particular, a
333 characteristic of the MTs that appeared to have emerged in recent years in our study population is the
334 presence of genes that encode particular toxin/antitoxin systems. These systems are present in a
335 variety of bacterial species both at a plasmid and chromosomal level, and involved in a variety of
336 cellular processes – including virulence, environmental stress response and niche adaptation [Van
337 Melderer and De Bast, 2009; Page and Peti, 2016; De La Cruz, *et al.*, 2013; Butt, *et al.*, 2014; Kim,
338 *et al.*, 2009; Wen, *et al.*, 2014]. The pan-GWAS analysis highlights the presence of virulence factors
339 in expanding MTs: in MT33 for instance the presence of a *ydcP* protease, a collagenase which
340 facilitates breaking of extracellular structures and a known virulence factor in other bacterial species
341 [Navais *et al.*, 2014], identified to be associated with pneumococcal IPD [Obolski, *et al.* 2019]; and
342 in MT109 and 74 of a hemolysin (pneumolysin) translocation ATP-binding protein gene, known
343 virulence factors for *S. pneumoniae*. Together, these observations indicate that the expanding
344 metabolic types accumulate characteristics that may affect niche competition and virulence.

345

346 Recent studies have described bacterial fitness in different terms, adapting its definition to the available
347 data. For instance, recent studies describe the negative frequency dependent selection in *S. pneumoniae*
348 populations, whereby bacterial fitness is affected by the frequency of rare accessory genes [Corander,
349 *et al.*, 2017; Azarian, *et al.*; 2020]. We have used growth curve analysis to infer relative, mixed-culture
350 bacterial fitness [Ram, *et al.*, 2018]. In combination with previous modelling analyses, the results
351 described in this work is consistent with a complex and diverse behaviour of a *S. pneumoniae*
352 population under vaccine pressure: serotype 23B MTs for instance, behaves closely to the VIMS model
353 description whereby the fitter genotype which was suppressed beforehand expands after vaccine
354 introduction due to niche clearance (Figure 3). On the other hand, serotype 38's MTs behave in
355 accordance with the hypothesis of an increase in frequency of AMR NVTs, driven by vaccination
356 [Obolski *et al.*, 2019]. An antibiotic susceptible MT of serotype 38 exhibited a higher intrinsic fitness,
357 as determined by the growth curve analysis. However, it appears that this MT was overtaken by another,
358 antibiotic resistant MT of serotype 38, when vaccination alleviated the competition pressure from VTs.

359 We also found that the most common strain of 23B (MT93) is less haemolytic than MT23 and more
360 successful in invading nasopharyngeal cells. On the other hand, serotype 38 MT120 stimulated less
361 IL-8 production, when compared to a less common metabolic genotype (MT28). Pro-inflammatory
362 interleukin-8 attracts neutrophils to the site of infection [Bickel, 1993] and therefore by evading the
363 immune system MT120 may have a competitive advantage.

364 The genetic and phenotypic analyses described here highlighted that the way the single strain evade
365 the immune system, or is more successful in transmitting or colonising different ecological niches, is
366 multifactorial. We cannot describe a common phenotype characteristic between all the genotypes that
367 have expanded recently, but we highlighted several differences that could help the success of each
368 genotype in different situations [Watkins, *et al.*, 2015].

369 The main limitation of this analysis is the lack of genomic data prior to the introduction of PCV in
370 Blantyre. However, we have been able to leverage this large dataset to capture ongoing changes in a
371 population with high vaccine coverage [Swarthout, *et al.*, 2020]. Because of the cross-sectional nature
372 of the surveillance contributing to the Blantyre collection we were not able to track the emergence of

373 MTs within individual hosts over time. Finally, as is inherent in observational studies, we have not
374 been able to attribute causality to routine vaccine introduction.

375 In conclusion, this study highlights that in this high burden vaccine-exposed population, AMR and a
376 range of genotypic and phenotypic traits facilitate the remarkably rapid expansion of MTs in the
377 community. Vaccine strategies that increase PCV valency may be insufficient to interrupt this
378 process [Colijn, *et al.*, 2020]. The multiple adaptations by these MTs extend beyond simple serotype
379 replacement, and successful adaptation could further undermine vaccine control and promote the
380 spread of AMR.

381

382 **Methods**

383 **Bacterial Isolates and Carriage Surveys**

384 The strains analysed in this study were isolated as part of a prospective observational study using
385 stratified random sampling to assess pneumococcal nasopharyngeal carriage in Blantyre, Malawi
386 [Swarthout, *at al.*, 2020]. In brief, sampling consisted of twice-annual rolling cross-sectional surveys
387 over the course of 4 years amongst PCV13-vaccinated children 2-7 years old, PCV13-unvaccinated
388 children 5-10 years old, and HIV-infected adults 18-40 years old on ART. Isolates from the HIV-
389 infected adults were sequenced from surveys 1, 2, 5 and 6 only.

390

391 **DNA Sequencing and Assembly**

392 NP swabs were stored in skim-milk-tryptone-glucose-glycerol (STGG) at -80C. After being thawed
393 and vortexed, 30 µL of STGG was plated on gentamicin-sheep blood agar (SBG; 7% sheep blood agar,
394 5 µL gentamicin/mL) and incubated overnight at 37 °C in 5% CO₂. Plates showing no *S. pneumoniae*
395 growth were incubated overnight a second time before being reported as negative. *S. pneumoniae* was
396 identified by colony morphology and optochin disc (Oxoid, Basingstoke, UK) susceptibility. The bile
397 solubility test was used on isolates with no or intermediate optochin susceptibility (zone
398 diameter < 14 mm). A single colony of confirmed pneumococcus was selected and grown on a new

399 SBG plate as before. Growth from this second plate was used for serotyping by latex agglutination
400 (ImmuLex™ 7-10-13-valent Pneumotest; Statens Serum Institute, Denmark) [Swarthout *et al* 2020].
401 DNA was extracted from an overnight lawn plate culture from isolates archived after serotyping, using
402 DNAeasy blood and tissue kit (Qiagen) following the manufacturer's guidelines and sequenced using
403 HiSeq4000 (paired-end library 2 × 150) platform at Oxford Genomics Centre UK.

404 Raw DNA reads were trimmed of low-quality ends and cleaned of adapters using Trimmomatic
405 software (ver. 0.32). De novo assembly was performed with SPAdes software (ver 3.8.0), using a
406 sample of 1,400,000 reads and k-mer values of 21, 33, 55, and 77. De novo assemblies were checked
407 for plausible length (between 1,900,000 and 2,200,000 bp), annotated using Prokka (ver. 1.12), and
408 checked for low-level contamination using Kraken (ver. 0.10.5). In cases for which more than 5% of
409 the contigs belonged to a species different from *Streptococcus pneumoniae*, the genome sequence was
410 not included in any further analysis. Resulting assemblies are available on pubmlst.org
411 (<https://pubmlst.org/organisms/streptococcus-pneumoniae> isolates numbers are in table S2). Metadata
412 of the strains used in this work are reported in table S2.

413

414 **Definition of Serotype, multilocus sequence type, global pneumococcal sequencing cluster and** 415 **AMR**

416 Serotypes were determined via DNA sequence, using the PneumoCaT software (Ver. 1.2.1,
417 <https://github.com/phe-bioinformatics/PneumoCaT>). Phenotypic serotype definition by latex
418 agglutination was used as validation of the genetic serotype definition, observing a correlation of over
419 90%, in alignment with previous estimations [Swarthout, *et al.*, 2021]. For the analyses in this work,
420 serotype determined by DNA sequencing was used.

421 Multilocus sequence types (MLST, STs) were assigned using the databases from the allelic profiles of
422 7 housekeeping genes (*adhP*, *pheS*, *atr*, *glnA*, *sdhA*, *glcK*, and *tkt*). BLASTn was used to align the
423 DNA assemblies to the DNA fragments typical of each allele for each house keeping gene (parameters:
424 E value 1e−10, minimum 95% identity, minimum 90% query coverage). This grouped strains into 200
425 unique STs. Strains which did not show a full set of housekeeping gene alleles or were not assigned to
426 any previously described ST (n = 783) were double-checked for sequence contamination and assigned

427 to a new sequence type definition. The database of MLST housekeeping fragments was downloaded
428 from pubmlst.com/Spneumoniae in October 2019. The GPSC genetic typing method (Global
429 Pneumococcal Sequence Clusters) was described in several recent publications [Lo, *et al.*, 2019;
430 Chaguza, *et al.*, 2018; Gladstone, *et al.*, 2019]. We collected the dataset to assign the GPSCs from
431 <https://www.pneumogen.net/gps/assigningGPSCs.html> and used PopPUNK [Lees, *et al.* 2019] to
432 cluster the isolates in the pre-defined GPSCs as described in Gladstone *et al.*, 2019. AMR gene
433 presence (for genes *cat*, *tetM*, *ermB*, and *mefA*) was detected via nucleotide-BLAST (E-value < 0.001,
434 sequence coverage and identity >80%). For penicillin resistance, MIC was genetically assessed using
435 the *pbp* genes allelic profile [Metcalf, *et al.*, 2016].

436

437 **Pangenome, definition of metabolic profiles and phylogenetic analyses**

438 In order to capture the total variability of the population, a pangenome was generated from the
439 combined isolates from surveys 1 to 8 using Roary (ver. 3.8.0). Parameters for each run were: 90% of
440 minimum BLASTp identity; MLC inflation value 1.5; with 99% of strains in which a gene must be
441 present to be considered “core”. Saturation of the pangenome was assessed. The core genome of this
442 bacterial population included 1061 genes which was consistent with previous estimates from Malawi
443 [Kulohoma, *et al.*, 2015]. The metabolic genes were selected via functional annotation of the core
444 genome (n=386 core metabolic genes, Watkins, *et al.*, 2015) through the eggNOG database
445 (<http://eggnogdb.embl.de>). Functional classes selected to define the core metabolic genome were: D -
446 Energy production and conversion, E - Amino acid transport and metabolism, F - Nucleotide transport
447 and metabolism, G - Carbohydrate transport and metabolism, H - Coenzyme transport and metabolism,
448 I - Lipid transport and metabolism, P - Inorganic ion transport and metabolism, Q - Secondary
449 metabolites biosynthesis, transport, and catabolism.

450 Metabolic profiles were defined using the following pipeline: (i) for each genome the allelic profile of
451 the metabolic core genes was defined using the Genome Comparator module of Bigsdb (bigsdb.com)
452 [Jolley, *et al.*, 2018]; (ii) the hamming distance between each allelic profile was calculated
453 (*hamming.dist* function of base R); (iii) the hamming distance between each isolate was used
454 hierarchically cluster the population (*hclust*); (iv) the hierarchical clustering dendrogram was cut at

455 midpoint to define the discrete metabolic profiles.

456 Maximum-Likelihood, recombination censored phylogeny was calculated with ClonalframeML, under
457 a generalized time-reversible model with 100 bootstrap replicates. Core genomes used to produce ML
458 phylogeny were calculated separately for the isolates belonging to the serotypes of interest (17F, 10A,
459 38, 34 and 23B) with Roary as described above, SNPsites (Ver 1.04) was used to identify the variable
460 part of the core genome alignment which was then used for phylogeny reconstruction, Root-to-tip
461 regression and phylogeny dating was calculated with BactDating R package
462 ("xavierdidelot/BactDating", 700000 permutations).

463 The pan-GWAS analyses were carried out using Scoary (<https://github.com/AdmiralenOla/Scoary>) as
464 described in Gori, *et al.*, 2020.

465

466 **Co-culture fitness and epithelial association/ invasion experiments**

467 Strains BVY5TE, BVY11B (serotype 23B, MT 23 and 93 respectively), BVY2DJ and BVY123
468 (serotype 38, MT 120 and 28 respectively) were selected for phenotypic evaluation (Table S1).

469 *In-vitro* broth culture was carried out in order to apply the pipeline described by Ram *et al.*, in 2019.
470 Isolates belonging to different MTs were harvested from a THY-10% glycerol stock and grown over-
471 night on a Columbia agar plate with 5% horse blood (CBA) plate. The plate was used to seed 10 ml
472 of Todd-Hewitt broth with 2.5% yeast extract (THY) to an optical density at 600nm (OD₆₀₀) of 0.5-1,
473 which was then diluted to an OD₆₀₀ 0.05 and used directly as starter in at least 16 200ul wells of a 96-
474 well plate. Each experiment also contained a mixture of 100 µl each of the two strains. Each plate was
475 incubated statically for 18-20h, at 37 °C, with 5% oxygen in a plate reader (Tecan Spark M20), and
476 OD₆₀₀ was measured every 15 minutes. In order to explore the possibility that ill-defined components
477 of THY may bias the differences seen, as well as to subject the cells to an environment more similar
478 to the one found in the nasopharynx, chemically defined minimal media proposed by Aprianto *et al*
479 [Aprianto *et al.*, 2018] was tested, but the isolates failed to grow in this medium.

480 Curveball (ver. 0.2.5) was used to fit each growth curve to a bacterial growth model and calculate each
481 strain-relative fitness by modelling the behaviour of each strain in co-culture. As curveball was

482 designed to calculate fitness in *E. coli* growth experiments, the growth curves were censored after each
483 strain reached the maximum OD₆₀₀, to correct for the characteristic *S. pneumoniae* autolysis.

484 Association and invasion experiments on human respiratory tract epithelial cells (Detroit 562) were
485 carried out as reported by Weight *et al.*, 2019. Briefly, human pharyngeal carcinoma Detroit 562
486 epithelial cells (ATCC_CCL-138) were grown in 10% FCS in alpha MEM media (Gibco). Confluent
487 Detroit 562 (typically day 8 post plating) were co-cultured with *S. pneumoniae* for 3 h in 1% FCS
488 alpha MEM (MOI ~1 cell:10 pneumococci). The medium was removed, and cells washed three times
489 in Hanks Buffer Saline Solution (HBSS+/, with calcium and magnesium, Gibco). Cells were
490 incubated in 1% saponin for 10 min at 37 °C and lysed by repetitive pipetting. Dilutions of bacteria
491 were plated on blood agar and colonies counted after 16 h. To quantify internalised bacteria, 100 µg/ml
492 gentamicin was added for 1 h to the cells, which were washed another three times, before incubating
493 with 1% Saponin and plating on blood agar plates. CFUs were counted after 16 h incubation at 37 °C,
494 5% CO₂.

495 For testing the haemolytic activity, bacteria were suspended in phenol free RPMI (Invitrogen) and
496 incubated with 2% red blood cells (EO labs) in a U-bottom 96 well plate for 30 minutes at 37°C / 5%
497 CO₂. Saponin was used as a positive control for cell lysis. The plate was centrifuged at 1500g for three
498 minutes and supernatant was transferred to a new plate to read absorbance at 540nm.

499 Finally, Detroit 562 cells were infected with *S. pneumoniae* for 6 hours and supernatant was collected
500 for analysis of IL-8 secretion. The protocol DuoSet® ELISA kit (R&D Systems) was followed
501 according to manufacturers' instructions.

502
503

504 **References**

- 505 1. Aprianto, R., Slager, J., Holsappel, S. & Veening, J. W. High-resolution analysis of the
506 pneumococcal transcriptome under a wide range of infection-relevant conditions. *Nucleic*
507 *Acids Res.* **46**, 9990–10006 (2018).
- 508 2. Azarian, T. *et al.* Frequency-dependent selection can forecast evolution in *Streptococcus*
509 *pneumoniae*. *PLoS Biol.* **18**, (2020).

- 510 3. Azarian, T. *et al.* The impact of serotype-specific vaccination on phylodynamic parameters of
511 *Streptococcus pneumoniae* and the pneumococcal pan-genome. *PLoS Pathog.* **14**, (2018).
- 512 4. Balsells, E., Guillot, L., Nair, H. & Kyaw, M. H. Serotype distribution of *Streptococcus*
513 *pneumoniae* causing invasive disease in children in the post-PCV era: A systematic review
514 and meta-analysis. *PLoS One* **12**, (2017).
- 515 5. Bar-Zeev, N. *et al.* Impact and effectiveness of 13-valent pneumococcal conjugate vaccine on
516 population incidence of vaccine and non-vaccine serotype invasive pneumococcal disease in
517 Blantyre, Malawi, 2006–18: prospective observational time-series and case-control studies.
518 *Lancet Glob. Heal.* **9**, e989–e998 (2021).
- 519 6. Ben-Shimol, S. *et al.* Impact of pneumococcal conjugate vaccines introduction on antibiotic
520 resistance of *Streptococcus pneumoniae* meningitis in children aged 5 years or younger,
521 israel, 2004 to 2016. *Eurosurveillance* **23**, (2018).
- 522 7. Bickel, M. The role of interleukin-8 in inflammation and mechanisms of regulation. *J.*
523 *Periodontol.* **64**, 456–60 (1993).
- 524 8. Brown, J. S., Gilliland, S. M., Spratt, B. G. & Holden, D. W. A Locus Contained within A
525 Variable Region of Pneumococcal Pathogenicity Island 1 Contributes to Virulence in Mice.
526 *Infect. Immun.* **72**, 1587–1593 (2004).
- 527 9. Butt, A. *et al.* The HicA toxin from *Burkholderia pseudomallei* has a role in persister cell
528 formation. *Biochem. J.* **459**, 333–344 (2014).
- 529 10. Chaguza, C. *et al.* Early signals of vaccine-driven perturbation seen in pneumococcal carriage
530 population genomic data. *Clin. Infect. Dis.* **70**, 1294–1303 (2020).
- 531 11. Cohen, C. *et al.* Effectiveness of the 13-valent pneumococcal conjugate vaccine against
532 invasive pneumococcal disease in South African children: a case-control study. *Lancet Glob.*
533 *Heal.* **5**, e359–e369 (2017).
- 534 12. Colijn, C., Corander, J. & Croucher, N. J. Designing ecologically optimized pneumococcal
535 vaccines using population genomics. *Nat. Microbiol.* **5**, 473–485 (2020).
- 536 13. Corander, J. *et al.* Frequency-dependent selection in vaccine-associated pneumococcal
537 population dynamics. *Nat. Ecol. Evol.* **1**, 1950–1960 (2017).
- 538 14. Croucher, N. J. *et al.* Diversification of bacterial genome content through distinct
539 mechanisms over different timescales. *Nat. Commun.* **5**, (2014).
- 540 15. Croucher, N. J. *et al.* Population genomic datasets describing the post-vaccine evolutionary
541 epidemiology of *Streptococcus pneumoniae*. *Sci. Data* **2**, (2015).
- 542 16. Croucher, N. J. *et al.* Selective and Genetic Constraints on Pneumococcal Serotype
543 Switching. *PLoS Genet.* **11**, (2015).

- 544 17. De la Cruz, M. A. *et al.* A Toxin-Antitoxin Module of *Salmonella* Promotes Virulence in
545 Mice. *PLoS Pathogens* vol. 9 1–13 (2013).
- 546 18. Everett, D. B. *et al.* Genetic characterisation of Malawian pneumococci prior to the roll-out
547 of the PCV13 vaccine using a high-throughput whole genome sequencing approach. *PLoS*
548 *One* **7**, (2012).
- 549 19. Ghahfarokhi, S. H. *et al.* Serotype distribution and antibiotic susceptibility of *Streptococcus*
550 *pneumoniae* isolates in Tehran, Iran: A surveillance study. *Infect. Drug Resist.* **13**, 333–340
551 (2020).
- 552 20. Gladstone, R. A. *et al.* International genomic definition of pneumococcal lineages, to
553 contextualise disease, antibiotic resistance and vaccine impact. *EBioMedicine* **43**, 338–346
554 (2019).
- 555 21. Gori, A. *et al.* Pan-GWAS of *Streptococcus agalactiae* Highlights Lineage-Specific Genes
556 Associated with Virulence and Niche Adaptation. *MBio* **11**, (2020).
- 557 22. Hammitt, L. L. *et al.* Effect of ten-valent pneumococcal conjugate vaccine on invasive
558 pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance
559 study. *Lancet* **393**, 2146–2154 (2019).
- 560 23. Huang, J. *et al.* Evolution and diversity of the antimicrobial resistance associated mobilome
561 in *Streptococcus suis*: A probable mobile genetic elements reservoir for other streptococci.
562 *Front. Cell. Infect. Microbiol.* **6**, (2016).
- 563 24. Jolley, K. A., Bray, J. E. & Maiden, M. C. J. Open-access bacterial population genomics:
564 BIGSdb software, the PubMLST.org website and their applications [version 1; referees: 2
565 approved]. *Wellcome Open Res.* **3**, (2018).
- 566
- 567 25. Kandasamy, R. *et al.* Persistent circulation of vaccine serotypes and serotype replacement
568 after 5 years of infant immunization with 13-valent pneumococcal conjugate vaccine in the
569 United Kingdom. *J. Infect. Dis.* **221**, 1361–1370 (2020).
- 570 26. Kim, Y., Wang, X., Ma, Q., Zhang, X. S. & Wood, T. K. Toxin-antitoxin systems in
571 *Escherichia coli* influence biofilm formation through YjgK (TabA) and fimbriae. *J.*
572 *Bacteriol.* **191**, 1258–1267 (2009).
- 573 27. Kulohoma, B. W. *et al.* Comparative genomic analysis of meningitis- and bacteremia-
574 causing pneumococci identifies a common core genome. *Infect. Immun.* **83**, 4165–4173
575 (2015).

- 576 28. Kwambana-Adams, B. *et al.* Rapid replacement by non-vaccine pneumococcal serotypes may
577 mitigate the impact of the pneumococcal conjugate vaccine on nasopharyngeal bacterial
578 ecology. *Sci. Rep.* **7**, (2017).
- 579 29. Lee, J. K. *et al.* Changes in the serotype distribution among antibiotic resistant carriage
580 *Streptococcus pneumoniae* isolates in children after the introduction of the extended-valency
581 pneumococcal conjugate vaccine. *J. Korean Med. Sci.* **32**, 1431–1439 (2017).
- 582 30. Lee, J. K. *et al.* Changes in the Serotype Distribution among Antibiotic Resistant Carriage
583 *Streptococcus pneumoniae* Isolates in Children after the Introduction of the Extended-
584 Valency Pneumococcal Conjugate Vaccine. *Open Forum Infect. Dis.* **4**, S462–S462 (2017).
- 585 31. Lees, J. A. *et al.* Fast and flexible bacterial genomic epidemiology with PopPUNK. *Genome*
586 *Res.* **29**, 304–316 (2019).
- 587 32. Lewnard, J. A. & Hanage, W. P. Making sense of differences in pneumococcal serotype
588 replacement. *The Lancet Infectious Diseases* vol. 19 e213–e220 (2019).
- 589 33. Lo, S. W. *et al.* Pneumococcal lineages associated with serotype replacement and antibiotic
590 resistance in childhood invasive pneumococcal disease in the post-PCV13 era: an
591 international whole-genome sequencing study. *Lancet Infect. Dis.* **19**, 759–769 (2019).
- 592 34. Lourenço, J. *et al.* Determinants of high residual post-PCV13 pneumococcal vaccine-type
593 carriage in Blantyre, Malawi: A modelling study. *BMC Med.* **17**, (2019).
- 594 35. Lourenço, J. *et al.* Lineage structure of *Streptococcus pneumoniae* may be driven by immune
595 selection on the groEL heat-shock protein. *Sci. Rep.* **7**, (2017).
- 596 36. McGee, L. *et al.* Nomenclature of major antimicrobial-resistant clones of *Streptococcus*
597 *pneumoniae* defined by the pneumococcal molecular epidemiology network. *J. Clin.*
598 *Microbiol.* **39**, 2565–2571 (2001).
- 599 37. Metcalf, B. J. *et al.* Using whole genome sequencing to identify resistance determinants and
600 predict antimicrobial resistance phenotypes for year 2015 invasive pneumococcal disease
601 isolates recovered in the United States. *Clin. Microbiol. Infect.* **22**, 1002.e1-1002.e8 (2016).
- 602 38. Musicha, P. *et al.* Trends in antimicrobial resistance in bloodstream infection isolates at a
603 large urban hospital in Malawi (1998–2016): a surveillance study. *Lancet Infect. Dis.* **17**,
604 1042–1052 (2017).
- 605 39. Mvula, H. *et al.* Predictors of uptake and timeliness of newly introduced pneumococcal and
606 rotavirus vaccines, and of measles vaccine in rural Malawi: A population cohort study. *PLoS*
607 *One* **11**, (2016).
- 608 40. Navais, R., Méndez, J., Pérez-Pascual, D., Cascales, D. & Guijarro, J. A. The *yrpAB* operon
609 of *Yersinia ruckeri* encoding two putative U32 peptidases is involved in virulence and
610 induced under microaerobic conditions. *Virulence* **5**, (2014).

- 611 41. Ngocho, J. S. *et al.* Effectiveness of pneumococcal conjugate vaccines against invasive
612 pneumococcal disease among children under five years of age in Africa: A systematic review.
613 *PLoS One* **14**, (2019).
- 614 42. Nzenze, S. A. *et al.* Temporal changes in pneumococcal colonization in HIV-infected and
615 HIV-uninfected mother-child pairs following transitioning from 7-valent to 13-valent
616 pneumococcal conjugate vaccine, Soweto, South Africa. *J. Infec. Dis.* **212**, 1082–1092
617 (2015).
- 618 43. O’Brien, K. L. *et al.* Burden of disease caused by *Streptococcus pneumoniae* in children
619 younger than 5 years: global estimates. *Lancet* **374**, 893–902 (2009).
- 620 44. O’Brien, K. L. PCV13 impact evaluations: The obvious and the unpredicted. *Pediatric*
621 *Infectious Disease Journal* vol. 32 264–265 (2013).
- 622 45. Obolski, U. *et al.* Identifying genes associated with invasive disease in *S. pneumoniae* by
623 applying a machine learning approach to whole genome sequence typing data. *Sci. Rep.* **9**,
624 (2019).
- 625 46. Obolski, U. *et al.* Vaccination can drive an increase in frequencies of antibiotic resistance
626 among nonvaccine serotypes of *Streptococcus pneumoniae*. *Proc. Natl. Acad. Sci. U. S. A.*
627 **115**, 3102–3107 (2018).
- 628 47. Page, R. & Peti, W. Toxin-antitoxin systems in bacterial growth arrest and persistence. *Nat.*
629 *Chem. Biol.* **12**, 208–214 (2016).
- 630 48. Ram, Y. *et al.* Predicting microbial growth in a mixed culture from growth curve data. *Proc.*
631 *Natl. Acad. Sci. U. S. A.* **116**, 14698–14707 (2019).
- 632 49. Roca, A. *et al.* Effect on nasopharyngeal pneumococcal carriage of replacing PCV7 with
633 PCV13 in the Expanded Programme of Immunization in The Gambia. *Vaccine* **33**, 7144–
634 7151 (2015).
- 635 50. Salvadori, G., Junges, R., Morrison, D. A. & Petersen, F. C. Competence in streptococcus
636 pneumoniae and close commensal relatives: Mechanisms and implications. *Frontiers in*
637 *Cellular and Infection Microbiology* vol. 9 (2019).
- 638 51. Sheppard, C. L. *et al.* The genomics of *Streptococcus Pneumoniae* carriage isolates from UK
639 children and their household contacts, Pre-PCV7 to Post-PCV13. *Genes (Basel)*. **10**, (2019).
- 640 52. Southern, J. *et al.* Pneumococcal carriage in children and their household contacts six years
641 after introduction of the 13-valent pneumococcal conjugate vaccine in England. *PLoS*
642 *ONE* **13**, e0195799 (2018).
- 643 53. Swarthout, T. D. *et al.* Evaluation of pneumococcal serotyping of nasopharyngeal-carriage
644 isolates by latex agglutination, whole-genome sequencing (PneumoCaT), and DNA
645 microarray in a high-pneumococcal-carriage-prevalence population in Malawi. *J. Clin.*
646 *Microbiol.* **59**, (2021).

- 647 54. Swarthout, T. D. *et al.* High residual carriage of vaccine-serotype *Streptococcus pneumoniae*
648 after introduction of pneumococcal conjugate vaccine in Malawi. *Nat. Commun.* **11**, (2020).
- 649 55. Tin Tin Htar, M. *et al.* The impact of routine childhood immunization with higher-valent
650 pneumococcal conjugate vaccines on antimicrobial-resistant pneumococcal diseases and
651 carriage: a systematic literature review. *Expert Review of Vaccines* vol. 18 1069–1089
652 (2019).
- 653 56. Vadlamudi, N. K., Chen, A. & Marra, F. Impact of the 13-valent pneumococcal conjugate
654 vaccine among adults: A systematic review and meta-analysis. *Clinical Infectious Diseases*
655 vol. 69 34–49 (2019).
- 656 57. Van Melder, L. & De Bast, M. S. Bacterial toxin-Antitoxin systems: More than selfish
657 entities? *PLoS Genetics* vol. 5 (2009).
- 658 58. Vestheim, D. F., Høiby, E. A., Aaberge, I. S. & Caugant, D. A. Impact of a pneumococcal
659 conjugate vaccination program on carriage among children in Norway. *Clin. Vaccin.*
660 *Immunol.* **17**, 325–334 (2010).
- 661 59. Wahl, B. *et al.* Burden of *Streptococcus pneumoniae* and *Haemophilus influenzae* type b
662 disease in children in the era of conjugate vaccines: global, regional, and national estimates
663 for 2000–15. *Lancet Glob. Health* **6**, e744–757 (2018).
- 664 60. Watkins, E. R. *et al.* Vaccination Drives Changes in Metabolic and Virulence Profiles of
665 *Streptococcus pneumoniae*. *PLoS Pathog.* **11**, (2015).
- 666 61. Weight, C. M. *et al.* Microinvasion by *Streptococcus pneumoniae* induces epithelial innate
667 immunity during colonisation at the human mucosal surface. *Nat. Commun.* **10**, (2019).
- 668 62. Weiser, J. N., Ferreira, D. M. & Paton, J. C. *Streptococcus pneumoniae*: Transmission,
669 colonization and invasion. *Nature Reviews Microbiology* vol. 16 355–367 (2018).
- 670 63. Wen, Y., Behiels, E. & Devreese, B. Toxin-Antitoxin systems: Their role in persistence,
671 biofilm formation, and pathogenicity. *Pathogens and Disease* vol. 70 240–249 (2014).

672

673

674 **Supplementary figures and tables**

675 **Figure S1 – frequency of STs, Serotypes and GPSCs in the three cohorts (vaccinated,**
676 **unvaccinated children and adults).** In (a) and (c) the frequency of genotypes present in at least 10
677 strains is shown, in (b) the frequency of serotypes present in at least 2 strains is shown. The
678 proportions shown in each plot are relative to the separate cohort.

679 **Figure S2 – Number of strains identified as a vaccine- or non-vaccine serotype, in common STs**
680 **(a) or GPSC (b) in time.** STs or GPSCs present in more than 10 isolates are shown. Non-typeable
681 serotype strain are excluded from this analysis.

682 **Figure S3 – (a) metabolic genotypes and (b) serotypes significantly different in distribution**
683 **between survey 1-4 and survey 5-8. Statistical association between MT (c) or serotype (d) and**
684 **penicillin resistance. (e) Penicillin resistance MIC in strains isolated during the early (survey 1-**
685 **4) or late (survey 5-8) stages of the carriage surveys .** Panels a, b, c and d show volcano plots
686 based on the p-value and the odds-ratio of fisher's exact tests, calculating the significance of: each
687 MT being differently distributed in survey 1-4 vs. 5-8 (a); each serotype being differently distributed
688 in survey 1-4 vs. 5-8 (b); each strain in a MT showing a penicillin MIC higher than 0.06 ug/ml (c);
689 each strain in a serotype showing a penicillin MIC higher than 0.06 ug/ml (d). Yellow and red lines
690 show a significance of <0.01 (red) <0.05 (yellow). Dots are colored with the same color scheme.

691 **Figure S4 – Presence and absence of AMR genes in strains belonging to serotype 23B (a), 34**
692 **(b), 10A (c), 17F (d), 38 (e).** Each barplot shows the number of strains in which the specific AMR
693 gene is present (+) or absent (-). Colors represent the metabolic genotype and are analogous to figure
694 3.

695 **Figure S5 - Core genome SNPs count for serotypes 38 (a), 17F (b), 34 (c), 10A (d), 23B (e).** Core
696 genome SNPs were normalised against the lower SNP count in the core-genome alignment in each
697 serotype [* F-test for equality of variances, p-value < 0.05]

698 **Figure S6 – Root-to-tip regression for strains isolated between 2015 and 2019 in Blantyre in the**
699 **context of this study, for serotypes 38 (a) and 17F (b).** Dots on the tree are coloured from blue to
700 red, according to their isolation date reflecting the dots on the linear regression plot. Nodes 85, 84
701 and 83 are highlighted in (a); Nodes 94 and node 95 are highlighted in (b)

702 **Figure S7 – Frequency of MTs, penicillin MIC and frequency of AMR genes in serotype 3 and**
703 **23F, during the 8 carriage surveys.** Each panel shows the frequency of isolation of each metabolic
704 profile (connected points), penicillin MIC of each isolate (box and whiskers plot, with points
705 representing each isolate), and presence of AMR genes in each metabolic type (regardless of
706 isolation time - barplot). Panels correspond to serotypes 3 (top) and 23F (bottom). The box and
707 whiskers plot in each panel also shows the number of isolates per survey at the top. Vertical blue
708 lines separate the early-late isolates.

709 **Figure S8 - Core genome SNPs count for serotype 38 – MT 120 strains isolated in Malawi and**
710 **in South Africa.** Core genome SNPs were normalised against the lower SNP count in the core-
711 genome alignment in each serotype [* F-test for equality of 2 variances, p-value < 0.05]

712 **Figure S9 - Phylogenetic trees for post-vaccine carriage isolates of serotype (a) 10A, (b) 17F, (c)**
713 **38, (d) 23B, (e) 34.** Each tree is annotated with the metabolic genotypes (MT, colored strip) and with

714 a binary heatmap showing gene presence (Green) or absence (Red) for the typical genes identified in
715 the most common metabolic profile in the late stages of carriage surveys.

716 **Table S1 – GWAS analysis results.** For each serotype, the genes significantly enriched in the
717 dominant MT are reported. Hypothetical proteins (as identified by automated Prokka annotation) are
718 excluded.

719 **Table S2 – Isolates sequenced in this study and associated metadata.**

720

721

722 **Acknowledgements**

723 We thank the individuals who participated in this study and the local schools and authorities for their
724 support. We are grateful to the study field teams (supported by Farouck Bonomali and Roseline
725 Nyirenda) and the MLW laboratory team. We are grateful to the hospitality of the QECH ART Clinic,
726 led by Ken Malisita. Our thanks also extend to the MLW laboratory management team (led by Brigitte
727 Denis) and the MLW data management team (led by Clemens Masesa). R.S.H., N.F., A.G. and T.S.
728 are supported by the National Institute for Health Research (NIHR) Global Health Research Unit on
729 Mucosal Pathogens using UK aid from the UK Government. The views expressed in this publication
730 are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social
731 Care. We thank the High-Throughput Genomics Group at the Wellcome Trust Centre for Human
732 Genetics (funded by Wellcome Trust grant reference 203141/Z/16/Z) for the generation of the
733 Sequencing data.

734 **Author contributions**

735 A.G., T.D.S., U.O., M.C.M., S.G., N.F., and R.S.H. designed the study and contributed to the
736 development of the methodology. T.D.S., N.F., and R.S.H. oversaw the study, data collection, and data
737 management. A.G., U.O., J.L. and S.G. developed genomic analysis. T. S., J. M. and C. B. oversaw
738 the genome extraction and pneumococcal serotyping. A.G., U.O and T.D.S wrote the first draft of the
739 paper. A.G., U.O., T.D.S., J.L., C.M.W., J.C., A.K., T.S.M., J.M., C.B., M.C.M., N.F., S.G., R.S.H.

740 contributed to subsequent drafts and read and approved the final version of the report

741 **Competing interests**

742 Authors declare no competing interests

743 **Funding**

744 This work was funded by Bill & Melinda Gates Foundation (OPP1117653 to R.S.H.), Medical
745 Research Council (MRC Grant Number: MR/N023129/1), a National Institute for Health Research
746 (NIHR) Global Health Research Unit on Mucosal Pathogens using UK aid from the UK Government
747 (16/136/46 to R.S.H.). The Malawi–Liverpool– Wellcome Clinical Research Programme is supported
748 by a Strategic Award from the Wellcome Trust (206545/Z/17/Z).

749 **Ethics approval and consent to participate**

750 The study protocol was approved by the College of Medicine Research and Ethics Committee,
751 University of Malawi (P.02/15/1677) and the Liverpool School of Tropical Medicine Research Ethics
752 Committee (14.056). Adult participants and parents/guardians of child participants provided written
753 informed consent, children 8-10 years old provided informed assent. This included consent for
754 publication.

755

756

Table 1 – Number of isolates, sequenced per community carriage survey. Surveys were conducted every 6 months, commencing in June 2015. Columns show the number of sequenced isolates and the percent of carriage identified in each of the 3 cohorts included in this study.

Survey #	Survey dates	Vaccinated children (2-7 y/o)		Unvaccinated children (5-10 y/o)		Adults (18-40 y/o HIV+ on ART)	
		Sequenced isolates #	% carriage	Sequenced isolates #	% carriage	Sequenced isolates #	% carriage
1	June 2015 August 2015	222	84.3	133	67.9	71	39.4
2	October 2015 April 2016	200	75.9	128	62.3	69	47.2
3	May 2016 October 2016	245	78.1	114	58.7	N/A	44.5
4	November 2016 April 2017	226	69.6	71	37.9	N/A	42.9
5	May 2017 October 2017	215	81	45	58.5	64	38.4
6	November 2017 June 2018	219	63.9	62	48.5	51	32.5
7	June 2018 December 2018	253	77.4	80	57.4	N/A	38.6
8	January 2019 June 2019	269	68.2	67	48.2	N/A	32.9

Figure 1 - Frequency of *S. pneumoniae* serotypes during carriage surveillance between June 2015 and June 2019 (surveys 1-8). Data points refer to: 2015-16 = community carriage surveys 1 and 2, 2016-17 = surveys 3-4, 2017-18 = surveys 5-6, 2018-19 = surveys 7-8. The dashed blue line separates early-stages of carriage surveys (June 2015 to April 2017, survey 1-4) from late-stages of carriage surveys (May 2017 to June 2019, survey 5-8). The upper row shows vaccine serotypes (1 to 23F), the following rows show non-vaccine serotypes. Serogroups are determined according to Pneumocat results. Non-typeable strains are excluded from the analysis. Error bars show standard error of the mean.




Table 2 – Capsular switch events. For each ST we present the most common serotype (major), the least common serotypes (minor serotype, described in the text as switch serotypes) and whether each serotype is included in PCV13 (VT and NVT).

ST	Major serotype		Minor serotype		ST	Major serotype		Minor serotype	
172	15B	NVT	15C	NVT	8672	3	VT	7F	NVT
			19F	VT	9523	18C	VT	18A	NVT
			15A	NVT				18F	NVT
			15BC	NVT	9552	20	NVT	3	VT
989	12F	NVT	19F	VT	10554	15A	NVT	11A	NVT
2059	23F	VT	13	NVT				19F	VT
3214	35A	NVT	11A	NVT				22A	NVT
			3	VT				9V	VT
			18A	NVT	10568	11A	NVT	3	VT
			18C	VT				11D	NVT
			35C	NVT	10587	7B_7C_40	NVT	19F	VT
4423	23B	NVT	23F	VT				19A	VT
5266	18C	VT	18B	NVT	10599	35B	NVT	14	VT
			22A	NVT				19A	VT
5435	3	VT	20	NVT				19F	VT
6279	23F	VT	23B	NVT	10603	15B	NVT	15BC	NVT
6441	48	NVT	3	VT				15C	NVT
7105	7B_7C_40	NVT	19A	VT				19F	VT
			19F	VT				15A	NVT
			3	VT	10660	6B	VT	6E	NVT
7653	6C	NVT	6D	NVT	11709	6B	VT	6E	NVT
			6A	VT	11770	16F	NVT	3	VT

Figure 2 - Hierarchical clustering dendrogram of *S. pneumoniae* metabolic types amongst carriage isolates (June 2015 - June 2019). The dendrogram is based on of the hamming distance between the different allelic profiles of the metabolic genes. Coloured strips represent the Metabolic type (also reported by an exterior number annotating the branch), the serotype, and the carriage survey group (early = survey 1 to 4, late = survey 5 to 8). MTs are defined by curtailing the dendrogram at half the maximum distance, indicated by the red line (n=148 discrete MTs, containing only MTs with more than 15 observations). The inset show a magnification of the dendrogram around serotype 17F/MT109.




Figure 3 - Shifts in metabolic profiles and penicillin MIC over time (surveys 1-8; June 2015 – June 2019). Boxes show the frequency of isolation of each metabolic profile per survey (“MT distribution in time”) and penicillin MIC of each isolate (box and whiskers plot, with points representing isolates, and numbers on top the number of isolates in each survey) for to serotypes 17F, 10A, 23B, 34 and 38. Vertical blue lines separate the early-late survey periods. Presence of AMR genes per serotype is shown in Figure S4.




Table 2 – Example of genes specific of MTs that expanded at late stages of carriage survey identified via pan-GWAS. Columns show the annotation of the genes or the gene system, the MTs and serotypes in which the gene was found, the sensitivity and specificity related to its presence in the MT reported in the table (and its absence in the other MTs). Full table is shown in supplementary material (Table S2). All p-values (adjusted using a Bonferroni correction) were <0.01, as reported by Scoary.

	MT	Serotype	Sens./Spec.
PTS system mannose-specific	120	38	100/100
PTS system sorbose-specific	120	38	100/100
PTS system galactitol-specific	93	23B	100/100
PTS system lactose-specific	93	23B	100/100
TA system pezA-pezT	120	38	100/100
TA system yefM-yoeB	93/120	23B/38	100/100
Competence-stimulating peptide type 1 - CSP1	120	38	100/100
Tetracycline resistance - tetM	120	38	95.6/100
Multidrug resistance ABC transporter - bmrA	93	23B	100/98.07
Lactococcin-G-processing and transport - lagD	109/74	17F/10A	93.1/92.1
Bacteriocin lactacin-F - lafA	109	17F	100/100
Alpha-hemolysin translocation ABP - HlyB	109/74	38/10A	100/100
Protease – ydcP	33	34	98.8/97.9

Figure 4 – Clusters of orthologous genes enriched in Serotype 10A (MT), 17F (MT), 23B (MT), 34 (MT), 38 (MT). Each barplot shows the number of genes in each functional class for the dominant metabolic type in the 5 serotypes, as reported by the pan-GWAS analysis. The columns refer to the functional classes “Metabolism” (MET), “Cellular processes and signaling” (CELL), “Information storage and processing” (INFO), or poorly characterized genes (UNKOWN).





Figure 5 – Growth curves and inferred in-vitro fitness of different metabolic types in serotype 23B and serotype 38. The growth curves of the MTs comprising serotype 23B (a) and 38 (b) separately (blue and red curves) and in an *in-vitro* co-culture (green curve). For each curve the MT or the combination of MTs is reported in parentheses. The table shows the growth parameters as predicted by Curveball (nu - deceleration parameter, q0 - initial physiological state, r - specific growth rate in low density [Ram *et al.*, 2019]).



Serotype	Metabolic genotype	max_growth_rate (h ⁻¹)	min_doubling_time (h)	Lag (h)	w - fitness
23B	23	1.05	0.75	2.88	1.00
23B	93	1.10	0.73	2.19	1.46
38	120	1.00	0.75	1.91	1.00
38	28	1.27	0.63	2.00	1.11

Figure 6 – Adhesion and invasion to epithelial cells, IL-8 secretion and haemolysis for MT122 and 29 (serotype 38) and MT91 and 24 (serotype 23B). (a) Number of bacteria adhered to epithelial cells, recovered after 2 hours of incubation, (b) Number of bacteria invading epithelial cells after 2 hours incubation, (c) IL-8 produced by epithelial cells, incubated with bacterial cells for 6 hours. NI = non-infected control. (d) haemolysis promoted by the different bacterial strains (lower OD corresponds to higher haemolysis), for different bacterial dilutions (neat ~ 1.5×10^6 bacterial cells. Results for 1/2, 1/5 and 1/10 dilutions are shown). Each experiment was repeated at least 3 times independently. In a, b, and c, dots on the bar plots show the result of each repetition. (* = $p < 0.05$. (a), (b), (d) : T-test; (c) one-way ANOVA).

